dc.contributor.author
Puccini, Marianna
dc.contributor.author
Rauch, Christian
dc.contributor.author
Jakobs, Kai
dc.contributor.author
Friebel, Julian
dc.contributor.author
Hassanein, Adel
dc.contributor.author
Landmesser, Ulf
dc.contributor.author
Rauch, Ursula
dc.date.accessioned
2024-08-13T13:41:22Z
dc.date.available
2024-08-13T13:41:22Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/44535
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-44247
dc.description.abstract
Purpose: Obese patients exhibit an overall increased platelet reactivity and a reduced sensitivity to antiplatelet therapy. The aim of this study is to evaluate the platelet reactivity measured by impedance aggregometry in overweight and obese patients and chronic coronary syndrome (CCS) that were treated with dual antiplatelet therapy (DAPT).
Methods: Platelet aggregation was assessed by impedance aggregometry in patients with CCS receiving DAPT (aspirin plus clopidogrel). We compared the platelet reactivity in patients with a normal weight versus overweight or obese patients. Furthermore, the correlation between the body mass index (BMI) and adenosine diphosphate- (ADP-) or thrombin receptor-activating peptide- (TRAP-) dependent platelet aggregation was analyzed.
Results: 64 patients were included in the study of which 35.9% were patients with normal weight. A higher ADP- and TRAP-dependent platelet reactivity was observed in overweight and obese patients (ADP: median 27 units (U) [IQR 13-39.5] vs. 7 U [6-15], p < 0.001 and TRAP: 97 U [73-118.5] vs. 85 U [36-103], p = 0.035). Significant positive correlations were observed between agonist-induced platelet reactivity and BMI.
Conclusion: Despite the use of DAPT, a higher platelet reactivity was found in overweight and obese patients with CCS. If these patients will benefit from treatment with more potent platelet inhibitors, it needs to be evaluated in future clinical trials.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
Platelet function
en
dc.subject
Dual antiplatelet therapy
en
dc.subject
Aggregometry
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Being Overweight or Obese Is Associated with an Increased Platelet Reactivity Despite Dual Antiplatelet Therapy with Aspirin and Clopidogrel
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.1007/s10557-022-07325-z
dcterms.bibliographicCitation.journaltitle
Cardiovascular Drugs and Therapy
dcterms.bibliographicCitation.number
4
dcterms.bibliographicCitation.originalpublishername
Springer Nature
dcterms.bibliographicCitation.pagestart
833
dcterms.bibliographicCitation.pageend
837
dcterms.bibliographicCitation.volume
37
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
Springer Nature DEAL
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
35211819
dcterms.isPartOf.issn
0920-3206
dcterms.isPartOf.eissn
1573-7241